# Friend or foe? Glial-vascular interactions in health and neurodegenerative disease.

- **DOI:** [10.1016/j.pharmr.2026.100143](https://doi.org/10.1016/j.pharmr.2026.100143)
- **Rating:** Sound (3.2 out of 5)
- **Verdict:** A cross-disease synthesis organizes glial-vascular mechanisms and research priorities, but its causal and therapeutic framing exceeds the evidence.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-16
- **Evaluation page:** https://www.nabu.science/paper/10.1016%2Fj.pharmr.2026.100143

## Key claims

1. glial-vascular interactions within the NGVU serve as both essential physiological mechanisms and critical pathological contributors across the spectrum of NDDs.
   - Support: Tentative
   - Type: Primary finding
   - Basis: heterogeneous postmortem and preclinical evidence does not establish causal pathological contribution across the full disease spectrum
   - Location: Conclusion, first paragraph
2. a convergent cascade of NGVU dysfunction can be identified across conditions.
   - Support: Tentative
   - Type: Secondary
   - Basis: uneven disease coverage and partly predicted cell communication limit certainty in a shared mechanistic cascade
   - Location: Glial–Vascular Interactions in Neurodegenerative Diseases, introductory paragraph; Fig. 3
3. the available evidence implicates astrocytic overexpression of VEGF-A as a central mechanistic axis linking glial dysfunction to vascular pathology in HD
   - Support: Tentative
   - Type: Secondary
   - Basis: a small body of mouse, patient-tissue, and iPSC studies limits the claim of a central disease mechanism
   - Location: Huntington Disease, final paragraph
4. These antiamyloid antibodies demonstrate that modulating glial-vascular interactions can yield clinically meaningful outcomes in neurodegenerative conditions
   - Support: Tentative
   - Type: Secondary
   - Basis: clinical antibody outcomes do not establish glial-vascular modulation when their NGVU effects remain underexplored
   - Location: Clinical Translation Success Stories, first paragraph

## Strengths

- **Cross-disease organization reveals shared research questions** The disease sections compare recurring vascular and glial changes while identifying condition-specific gaps, including underexplored oligodendrocyte-vascular interactions.
  - Dimension: contribution
  - Location: Glial–Vascular Interactions in Neurodegenerative Diseases; Figures 3–4
- **Mechanistic narrative engages selected counter-evidence directly** The BBB discussion includes microglial depletion without barrier loss, and later sections acknowledge failed trials and vascular consequences of removing microglia.
  - Dimension: methodological rigour
  - Location: Blood-Brain Barrier Maintenance; Novel Cellular and Molecular Strategies; Drug Delivery Systems for Neurogliovascular Unit Targeting
- **Methods roadmap links inference with function** Future Directions connects vascular-enriched sequencing and spatial approaches with barrier and hemodynamic measurements, providing a concrete route for testing candidate interactions.
  - Dimension: application pathway
  - Location: Glia and Vascular Cell Heterogeneity; Tools to Assess Glial–Vascular Crosstalk

## Limitations

- **Literature selection remains undocumented beyond tables** Selection criteria are supplied for the illustrative therapeutic tables but not for the broad empirical synthesis, leaving the overall coverage boundaries unspecified.
  - Dimension: methodological rigour
  - Location: Introduction through Conclusion; Development of Glial–Vascular Targeted Therapeutics
- **Therapeutic conclusions exceed acknowledged mechanistic knowledge** Anti-amyloid antibodies are presented as demonstrating successful glial-vascular modulation despite the same passage stating that their NGVU effects remain underexplored. Table 1 and its narrative also disagree on development-stage distributions.
  - Dimension: positioning
  - Location: Clinical Translation Success Stories; Table 1; Development of Glial–Vascular Targeted Therapeutics
- **Causal framing exceeds heterogeneous disease evidence** The Conclusion attributes disease onset and progression to disrupted interactions, while the Abstract and disease sections leave causal ordering unresolved. Postmortem observations and predictive interaction analyses cannot establish that broad causal proposition.
  - Dimension: reporting
  - Location: Abstract; Parkinson Disease; Tools to Assess Glial–Vascular Crosstalk; Conclusion

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - Minor reporting notes (1):
    - Descriptive: "Among the direct therapeutics listed in Table 1, the pipeline includes 7 US Food and Drug Administration (FDA)-approved therapies, 5 agents in clinical trials, and 16 therapeutics in preclinical development." (Development of Glial–Vascular Targeted Therapeutics, opening paragraph) vs "MSCsBBB/multipleAD, PD, stroke, MSClinical trialsCell/gene therapyIsaković al200LaromestrocelVascular, inflammationAD, ALSPhase 2a trialCell/gene therapyRash et al201PDGF-BBPericytesBBB dysfunction, Parkinson’sClinical trialsGrowth factorLi et al202AST-004Astrocytes/neuroprotectionStroke, TBI, ADPhase 1bSmall moleculeManna et al203PLX3397 (pexidartinib)MicrogliaNDD, brain cancerPhase 1–3 trialSmall moleculeWen et al204LY3022855 (IMC-CS4)MicrogliaCancer (potential NDD)Phase 1Monoclonal antibodyAutio et al205Carboplatin + FUS-BBBOBBBBrain cancerPhase 1/2aPhysical + chemotherapyCarpentier et al206GantenerumabVascular/BBB (amyloid clearance)ADPhase 3 failedMonoclonal antibodyBateman et al207SolanezumabVascular/BBB (amyloid clearance)ADPhase 3 failedMonoclonal antibodyDoggrell208AL002a (TREM2 agonist)MicrogliaADPhase 2 failedMonoclonal antibodyLong et al209PLX5622MicrogliaAD, MSPreclinicalSmall molecule (CSF1R inhibitor)Green et al210GW2580MicrogliaPD, MSPreclinicalSmall Molecule (CSF1R inhibitor)Borjini et al211JNJ-40346527MicrogliaAD, brain cancerPreclinical, phase 1/2 (cancer)Small molecule (CSF1R inhibitor)Mancuso et al,234 von Tresckow et al212Wnt3a/CHIR99021BBB/endothelialBBB dysfunction (cancer and NDD)PreclinicalSmall moleculeLaw and Zheng213SW033291 (15-PGDH inhibitor)BBB, microglia/PVMAD, TBIPreclinicalSmall moleculeKoh et al214EPPSBBB/amyloid clearanceADPreclinicalSmall moleculeKim et al215ThalidomidePericytesBBB dysfunction, Alzheimer’sPreclinical/phase 2aSmall moleculeDecourt et al2167,8-DihydroxyflavoneOligodendrocytes/neuronsAD, depressionPreclinicalSmall moleculeDevi and Ohno217LM22A-4Oligodendrocytes/neuronsAD, HD, Rett syndromePreclinicalSmall moleculeKazim and Iqbal218AL04BBB/endothelialNDDPreclinicalFusion proteinPanaiotov219TDP6 (BDNF mimetic)OligodendrocytesDemyelinating diseasesPreclinicalPeptide mimeticSchirò et al220" (Table 1, rows MSCs through TDP6). Counting Table 1's printed stage labels gives 7 approved rows, 7 clinical-trial rows without a preclinical label, 3 failed-trial rows, and 11 rows containing a preclinical label, including 2 with mixed preclinical/clinical labels, rather than the narrative's 7/5/16 partition. → Changes the size materially
- **Reporting and transparency:** Noted. Citation assignments differ between the natalizumab table entry and clinical narrative, and between repeated descriptions of HD pericyte and iPSC evidence; the supplied text does not establish which assignments are correct.
  - Conflict of interest: declared
- **Reference integrity:** Clean
  - 240 references in manuscript
  - 239 of 239 checkable references found in an index
  - 1 are books, websites or datasets — counted, but not index-checkable
  - 88 DOIs could not be checked:
    - #151 van den Bosch A.M.R. van der Poel M. Fransen N.L. Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation Nat Commun 15 1 2024 1667 10.1038/s41467-024-46068-3 38396116 PMC10891081 (beyond the 150 accuracy-lookup cap)
    - #152 Kukanja P. Langseth C.M. Rubio Rodríguez-Kirby L.A. Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology Cell 187 8 2024 1990 2009.e19 10.1016/j.cell.2024.02.030 38513664 (beyond the 150 accuracy-lookup cap)
    - #153 Hansen C.E. Kamermans A. Mol K. Inflammation-induced TRPV4 channels exacerbate blood-brain barrier dysfunction in multiple sclerosis J Neuroinflammation 21 1 2024 72 10.1186/s12974-024-03069-9 38521959 PMC10960997 (beyond the 150 accuracy-lookup cap)
    - #154 Elkjaer M.L. Röttger R. Baumbach J. Illes Z. A systematic review of tissue and single cell transcriptome/proteome studies of the brain in multiple sclerosis Front Immunol 13 2022 761225 10.3389/fimmu.2022.761225 PMC8924618 35309325 (beyond the 150 accuracy-lookup cap)
    - #155 Gnanaguru G. Tabor S.J. Bonilla G.M. Microglia refine developing retinal astrocytic and vascular networks through the complement C3/C3aR axis Development 150 5 2023 dev201047 10.1242/dev.201047 PMC10110418 36762625 (beyond the 150 accuracy-lookup cap)
    - #156 Agarwal M. Khan S. Plasma lipids as biomarkers for Alzheimer's disease: a systematic review Cureus 12 12 2020 e12008 10.7759/cureus.12008 PMC7797449 33457117 (beyond the 150 accuracy-lookup cap)
    - #157 Gupta A. Uthayaseelan K. Uthayaseelan K. Alzheimer’s disease and stroke: a tangled neurological conundrum Cureus 14 5 2022 e25005 10.7759/cureus.25005 PMC9194877 35712342 (beyond the 150 accuracy-lookup cap)
    - #158 Singh-Reilly N. Graff-Radford J. Li D. A β 42/40 and p-tau 181 as disease biomarkers in atypical Alzheimer's disease J Alzheimers Dis 105 3 2025 923 931 10.1177/13872877251333450 40267266 PMC12208405 (beyond the 150 accuracy-lookup cap)
    - #159 Etuzé T. Fosset L. Vivien D. Roussel B.D. Lemarchand E. Endothelial tPA-dependent recruitment of microglia to vessels protects the blood-brain barrier after stroke in mice bioRxiv Preprint posted online January 16, 2025 632943 10.1101/2025.01.14.632943 PMC13151305 41904577 (beyond the 150 accuracy-lookup cap)
    - #160 Yenari M.A. Xu L. Tang X.N. Qiao Y. Giffard R.G. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro Stroke 37 4 2006 1087 1093 10.1161/01.STR.0000206281.77178.ac 16497985 (beyond the 150 accuracy-lookup cap)
    - #161 Jolivel V. Bicker F. Binamé F. Perivascular microglia promote blood vessel disintegration in the ischemic penumbra Acta Neuropathol 129 2 2015 279 295 10.1007/s00401-014-1372-1 25500713 (beyond the 150 accuracy-lookup cap)
    - #162 Chen A.Q. Fang Z. Chen X.L. Microglia-derived TNF- α mediates endothelial necroptosis aggravating blood brain–barrier disruption after ischemic stroke Cell Death Dis 10 7 2019 487 10.1038/s41419-019-1716-9 31221990 PMC6586814 (beyond the 150 accuracy-lookup cap)
    - #163 Hossein Geranmayeh M. Farokhi-Sisakht F. Sadigh-Eteghad S. Rahbarghazi R. Mahmoudi J. Farhoudi M. Simultaneous pericytes and M2 microglia transplantation improve cognitive function in mice model of mPFC ischemia Neuroscience 529 2023 62 72 10.1016/j.neuroscience.2023.08.010 37591334 (beyond the 150 accuracy-lookup cap)
    - #164 Sakuma R. Kawahara M. Nakano-Doi A. Brain pericytes serve as microglia-generating multipotent vascular stem cells following ischemic stroke J Neuroinflammation 13 1 2016 57 10.1186/s12974-016-0523-9 26952098 PMC4782566 (beyond the 150 accuracy-lookup cap)
    - #165 Nirwane A. Yao Y. SMA low/undetectable pericytes differentiate into microglia- and macrophage-like cells in ischemic brain Cell Mol Life Sci 79 5 2022 264 10.1007/s00018-022-04322-1 35482211 PMC11073453 (beyond the 150 accuracy-lookup cap)
    - #166 Ye Q. Jo J. Wang C.Y. Astrocytic Slc4a4 regulates blood-brain barrier integrity in healthy and stroke brains via a CCL2-CCR2 pathway and NO dysregulation Cell Rep 43 5 2024 114193 10.1016/j.celrep.2024.114193 PMC11210630 38709635 (beyond the 150 accuracy-lookup cap)
    - #167 Williamson M.R. Fuertes C.J.A. Dunn A.K. Drew M.R. Jones T.A. Reactive astrocytes facilitate vascular repair and remodeling after stroke Cell Rep 35 4 2021 109048 10.1016/j.celrep.2021.109048 PMC8142687 33910014 (beyond the 150 accuracy-lookup cap)
    - #168 Wardlaw J.M. Smith C. Dichgans M. Small vessel disease: mechanisms and clinical implications Lancet Neurol 18 7 2019 684 696 10.1016/S1474-4422(19)30079-1 31097385 (beyond the 150 accuracy-lookup cap)
    - #169 Quick S. Procter T.V. Moss J. Loss of the heterogeneous expression of flippase ATP11B leads to cerebral small vessel disease in a normotensive rat model Acta Neuropathol 144 2 2022 283 303 10.1007/s00401-022-02441-4 35635573 PMC9288385 (beyond the 150 accuracy-lookup cap)
    - #170 Low A. Mak E. Malpetti M. In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer’s disease J Neurol Neurosurg Psychiatry 92 1 2021 45 52 10.1136/jnnp-2020-323894 PMC7803899 32917821 (beyond the 150 accuracy-lookup cap)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
